Merus NV (MRUS) Expected to Announce Quarterly Sales of $7.47 Million

Wall Street brokerages predict that Merus NV (NASDAQ:MRUS) will post $7.47 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Merus’ earnings, with the lowest sales estimate coming in at $4.66 million and the highest estimate coming in at $10.27 million. Merus posted sales of $12.19 million in the same quarter last year, which would indicate a negative year over year growth rate of 38.7%. The business is expected to announce its next quarterly earnings report on Thursday, July 25th.

According to Zacks, analysts expect that Merus will report full year sales of $29.91 million for the current year, with estimates ranging from $18.62 million to $41.19 million. For the next fiscal year, analysts expect that the company will report sales of $49.95 million, with estimates ranging from $18.62 million to $81.28 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Merus.

A number of brokerages have recently issued reports on MRUS. BidaskClub raised shares of Merus from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 9th. Royal Bank of Canada upgraded shares of Merus from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $18.00 to $23.00 in a research note on Wednesday, April 3rd. Zacks Investment Research downgraded shares of Merus from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Berenberg Bank started coverage on shares of Merus in a report on Wednesday, March 27th. They set a “buy” rating and a $35.00 price target on the stock. Finally, ValuEngine raised shares of Merus from a “sell” rating to a “hold” rating in a report on Wednesday, March 6th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $23.00.

Large investors have recently modified their holdings of the business. Artal Group S.A. purchased a new position in Merus during the fourth quarter valued at approximately $2,886,000. JPMorgan Chase & Co. lifted its holdings in Merus by 33.8% during the third quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after purchasing an additional 4,476 shares in the last quarter. Aquilo Capital Management LLC lifted its holdings in Merus by 3.6% during the third quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after purchasing an additional 44,799 shares in the last quarter. Morgan Stanley lifted its holdings in Merus by 74.3% during the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after purchasing an additional 30,538 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Merus by 10.3% during the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,100 shares in the last quarter. 53.06% of the stock is currently owned by institutional investors and hedge funds.

MRUS traded up $0.55 during midday trading on Thursday, reaching $15.70. The company had a trading volume of 32,741 shares, compared to its average volume of 37,435. Merus has a 12-month low of $11.00 and a 12-month high of $26.74. The stock has a market cap of $357.19 million, a price-to-earnings ratio of -8.53 and a beta of -0.06.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.